Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing
This study has been completed.
Study NCT00381173 Information provided by Eisai Inc.
First Received: September 26, 2006 Last Updated: April 15, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Ovarian Cancer
Prostate Cancer
Colon Cancer
Renal Cancer
Additional conditions recognized in this trial
Breast Neoplasms
Carcinoma, Renal Cell
Colonic Neoplasms
Kidney Neoplasms
Ovarian Neoplasms
Prostatic Neoplasms
More general conditions related to this trial
Adenocarcinoma
Adnexal Diseases
Breast Diseases
Carcinoma
Colonic Diseases
Colorectal Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Genital Diseases, Female
Genital Diseases, Male
Genital Neoplasms, Female
Genital Neoplasms, Male
Gonadal Disorders
Intestinal Diseases
Intestinal Neoplasms
Kidney Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Ovarian Diseases
Prostatic Diseases
Skin Diseases
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Additional drug interventions recognized in this trial
Cyclophosphamide
More general drug interventions related to this trial
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Eisai Inc.
Back to top of Main Content
